nach oben

Erschienen in:

06.02.2018 | Letter to Editor

Hematologic Manifestations of Deficiency of Adenosine Deaminase 2 (DADA2) and Response to Tumor Necrosis Factor Inhibition in DADA2-Associated Bone Marrow Failure

verfasst von: Thomas F. Michniacki, Mark Hannibal, Charles W. Ross, David G. Frame, Adam S. DuVall, Rami Khoriaty, Mark T. Vander Lugt, Kelly J. Walkovich

Erschienen in: Journal of Clinical Immunology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Excerpt

To the Editor, …

Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, Zavialov AV, et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med. 2014;370(10):911–20. https://doi.org/10.1056/NEJMoa1307361.CrossRefPubMedPubMedCentral

Navon Elkan P, Pierce SB, Segel R, Walsh T, Barash J, Padeh S, et al. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med. 2014;370(10):921–31. https://doi.org/10.1056/NEJMoa1307362.CrossRefPubMed

Bras J, Guerreiro R, Santo GC. Mutant ADA2 in vasculopathies. N Engl J Med. 2014;371(5):478–80. https://doi.org/10.1056/NEJMc1405506#SA3.CrossRefPubMed

Van Eyck L, Liston A, Mutant WC. ADA2 in vasculopathies. N Engl J Med. 2014;371(5):480.PubMed

van Montfrans J, Zavialov A, Zhou Q. Mutant ADA2 in vasculopathies. N Engl J Med. 2014;371(5):478. https://doi.org/10.1056/NEJMc1405506#SA1.CrossRefPubMed

Ben-Ami T, Revel-Vilk S, Brooks R, Shaag A, Hershfield MS, Kelly SJ, et al. Extending the clinical phenotype of adenosine deaminase 2 deficiency. J Pediatr. 2016;177:316–20. https://doi.org/10.1016/j.jpeds.2016.06.058.CrossRefPubMed

Van Montfrans JM, EAR H, KPJ B, EAM H, Hak EA, Nederkoorn PJ, et al. Phenotypic variability in patients with ADA2 deficiency due to identical homozygous R169Q mutations. Rheumatology (Oxford). 2016;55(5):902–10. https://doi.org/10.1093/rheumatology/kev439.CrossRef

Nanthapisal S, Murphy C, Omoyinmi E, Hong Y, Standing A, Berg S, et al. Deficiency of adenosine deaminase Type 2: a description of phenotype and genotype in fifteen cases. Arthritis Rheumatol (Hoboken, NJ). 2016;68(9):2314–22.CrossRef

Caorsi R, Penco F, Schena F, Gattorno M. Monogenic polyarteritis: the lesson of ADA2 deficiency. Pediatr Rheumatol Online J. 2016;14(1):51. https://doi.org/10.1186/s12969-016-0111-7.CrossRefPubMedPubMedCentral

10.

Batu ED, Karadag O, Taskiran EZ, Kalyoncu U, Aksentijevich I, Alikasifoglu M, et al. A case series of adenosine deaminase 2-deficient patients emphasizing treatment and genotype-phenotype correlations. J Rheumatol. 2015;42(8):1532–4. https://doi.org/10.3899/jrheum.150024.CrossRefPubMed

11.

Uettwiller F, Sarrabay G, Rodero MP, Rice GI, Lagrue E, Marot Y, et al. ADA2 deficiency: case report of a new phenotype and novel mutation in two sisters. RMD Open. 2016;2(1):e000236. https://doi.org/10.1136/rmdopen-2015-000236.CrossRefPubMedPubMedCentral

12.

Hashem H, Egler R, Dalal J. Refractory pure red cell aplasia manifesting as deficiency of adenosine deaminase J Pediatr Hematol Oncol 2017.

13.

Maciejewski J, Selleri C, Anderson S, Young NS. Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood. 1995;85(11):3183–90.PubMed

14.

Hara T, Ando K, Tsurumi H, Moriwaki H. Excessive production of tumor necrosis factor-alpha by bone marrow T lymphocytes is essential in causing bone marrow failure in patients with aplastic anemia. Eur J Haematol. 2004;73(1):10–6. https://doi.org/10.1111/j.1600-0609.2004.00259.x.CrossRefPubMed

15.

Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90(8):1128–32.PubMed

16.

Schepp J, Bulashevska A, Mannhardt-Laakmann W, Cao H, Yang F, Seidl M, et al. Deficiency of adenosine deaminase 2 causes antibody deficiency. J Clin Immunol. 2016;36(3):179–86. https://doi.org/10.1007/s10875-016-0245-x.CrossRefPubMed

17.

Garg N, Kasapcopur O, Foster J, Barut K, Tekin A, Kızılkılıç O, et al. Novel adenosine deaminase 2 mutations in a child with a fatal vasculopathy. Eur J Pediatr. 2014;173(6):827–30. https://doi.org/10.1007/s00431-014-2320-8.CrossRefPubMed

18.

Van Eyck L, Hershfield MS, Pombal D, Kelly SJ, Ganson NJ, Moens L, et al. Hematopoietic stem cell transplantation rescues the immunologic phenotype and prevents vasculopathy in patients with adenosine deaminase 2 deficiency. J Allergy Clin Immunol. 2015;135(1):283–287.e5. https://doi.org/10.1016/j.jaci.2014.10.010.CrossRefPubMedPubMedCentral

19.

Belot A, Wassmer E, Twilt M, Lega J-C, Zeef LA, Oojageer A, et al. Mutations in CECR1 associated with a neutrophil signature in peripheral blood. Pediatr Rheumatol Online J. 2014;12(1):44. https://doi.org/10.1186/1546-0096-12-44.CrossRefPubMedPubMedCentral

20.

Gonzalez Santiago TM, Zavialov A, Saarela J, Seppanen M, Reed AM, Abraham RS, et al. Dermatologic features of ADA2 deficiency in cutaneous polyarteritis nodosa. JAMA Dermatol. 2015;151(11):1230–4. https://doi.org/10.1001/jamadermatol.2015.1635.CrossRefPubMed

21.

Westendorp WF, Nederkoorn PJ, Aksentijevich I, Hak AE, Lichtenbelt KD, Braun KPJ. Unexplained early-onset lacunar stroke and inflammatory skin lesions: consider ADA2 deficiency. Neurology. 2015;84(20):2092–3. https://doi.org/10.1212/WNL.0000000000001581.CrossRefPubMedPubMedCentral

22.

Fellmann F, Angelini F, Wassenberg J, Perreau M, Arenas Ramirez N, Simon G, et al. IL-17 receptor A and adenosine deaminase 2 deficiency in siblings with recurrent infections and chronic inflammation. J Allergy Clin Immunol. 2016;137(4):1189-1196-2–1196.e2. https://doi.org/10.1016/j.jaci.2015.07.053.CrossRefPubMed

23.

Elbracht M, Mull M, Wagner N, Kuhl C, Abicht A, Kurth I, et al. Stroke as initial manifestation of adenosine deaminase 2 deficiency. Neuropediatrics. 2017;48(2):111–4. https://doi.org/10.1055/s-0036-1597611.PubMed

24.

Keer N, Hershfield M, Caskey T, Unizony S. Novel compound heterozygous variants in CECR1 gene associated with childhood onset polyarteritis nodosa and deficiency of ADA2. Rheumatology (Oxford). 2016;55(6):1145–7. https://doi.org/10.1093/rheumatology/kew050.CrossRef

25.

Hsu AP, West RR, Calvo KR, Cuellar-Rodriguez J, Parta M, Kelly SJ, et al. Adenosine deaminase type 2 deficiency masquerading as GATA2 deficiency: successful hematopoietic stem cell transplantation. J Allergy Clin Immunol. 2016;138(2):628–630.e2. https://doi.org/10.1016/j.jaci.2016.03.016.CrossRefPubMedPubMedCentral

26.

Poswar F de O, da Fonseca RMT, de Albuquerque LCP, Zhou Q, Jardim LB, Monte TL, et al. Adenosine deaminase 2 deficiency presenting as spastic paraplegia and systemic vasculitis. J Neurol. 2016;263(4):818–20. https://doi.org/10.1007/s00415-016-8070-y.CrossRef

27.

Hashem H, Kumar AR, Müller I, Babor F, Bredius R, Dalal J, et al. Hematopoietic stem cell transplantation rescues the hematological, immunological, and vascular phenotype in DADA2. Blood. 2017;03

28.

Sahin S, Adrovic A, Barut K, Ugurlu S, Turanli ET, Ozdogan H, et al. Clinical, imaging and genotypical features of three deceased and five surviving cases with ADA2 deficiency. Rheumatol Int 2017;

29.

Caorsi R, Penco F, Grossi A, Insalaco A, Omenetti A, Alessio M, et al. ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study. Ann Rheum Dis. 2017;76(10):1648–56. https://doi.org/10.1136/annrheumdis-2016-210802.CrossRefPubMed

30.

Skrabl-Baumgartner A, Plecko B, Schmidt WM, König N, Hershfield M, Gruber-Sedlmayr U, et al. Autoimmune phenotype with type I interferon signature in two brothers with ADA2 deficiency carrying a novel CECR1 mutation. Pediatr Rheumatol Online J. 2017;15(1):67. https://doi.org/10.1186/s12969-017-0193-x.CrossRefPubMedPubMedCentral

31.

Schepp J, Proietti M, Frede N, Buchta M, Hübscher K, Rojas Restrepo J, et al. Screening of 181 patients with antibody deficiency for deficiency of adenosine deaminase 2 sheds new light on the disease in adulthood. Arthritis & Rheumatol (Hoboken, NJ). 2017.

32.

Spinner MA, Sanchez LA, Hsu AP, Shaw PA, Zerbe CS, Calvo KR, et al. GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood. 2014;123(6):809–21.CrossRefPubMedPubMedCentral

33.

Fogarty PF, Yamaguchi H, Wiestner A, Baerlocher GM, Sloand E, Zeng WS, et al. Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA. Lancet. 2003;362(9396):1628–30. https://doi.org/10.1016/S0140-6736(03)14797-6.CrossRefPubMed

34.

Huck K, Hanenberg H, Gudowius S, Fenk R, Kalb R, Neveling K, et al. Delayed diagnosis and complications of Fanconi anaemia at advanced age—a paradigm. Br J Haematol. 2006;133(2):188–97. https://doi.org/10.1111/j.1365-2141.2006.05998.x.CrossRefPubMed

35.

Zatterale A, Calzone R, Renda S, Catalano L, Selleri C, Notaro R, et al. Identification and treatment of late onset Fanconi’s anemia. Haematologica. 1995;80(6):535–8.PubMed

36.

Dokal I, Vulliamy T. Inherited aplastic anaemias/bone marrow failure syndromes. Blood Rev. 2008;22(3):141–53. https://doi.org/10.1016/j.blre.2007.11.003.CrossRefPubMed

37.

Babushok DV, Bessler M. Genetic predisposition syndromes: when should they be considered in the work-up of MDS? Best Pract Res Clin Haematol. 2015;28(1):55–68. https://doi.org/10.1016/j.beha.2014.11.004.CrossRefPubMed

38.

Chen Y, Zou Z, Wu Z, Zhao Z, Luo X, Xie C, et al. TNF-α-induced programmed cell death in the pathogenesis of acquired aplastic anemia. Expert Rev Hematol. 2015;8(4):515–26. https://doi.org/10.1586/17474086.2015.1049593.CrossRefPubMed

39.

Demeter J, Messer G, Schrezenmeier H. Clinical relevance of the TNF-alpha promoter/enhancer polymorphism in patients with aplastic anemia. Ann Hematol. 2002;81(10):566–9. https://doi.org/10.1007/s00277-002-0544-6.CrossRefPubMed

Titel: Hematologic Manifestations of Deficiency of Adenosine Deaminase 2 (DADA2) and Response to Tumor Necrosis Factor Inhibition in DADA2-Associated Bone Marrow Failure
verfasst von: Thomas F. Michniacki
Mark Hannibal
Charles W. Ross
David G. Frame
Adam S. DuVall
Rami Khoriaty
Mark T. Vander Lugt
Kelly J. Walkovich
Publikationsdatum: 06.02.2018
Verlag: Springer US
Erschienen in: Journal of Clinical Immunology / Ausgabe 2/2018
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-018-0480-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Hematologic Manifestations of Deficiency of Adenosine Deaminase 2 (DADA2) and Response to Tumor Necrosis Factor Inhibition in DADA2-Associated Bone Marrow Failure

Excerpt

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

IgM Augments Complement Bactericidal Activity with Serum from a Patient with a Novel CD79a Mutation

Hypersensitive Pneumonitis: an Initial Presentation of Chronic Granulomatous Disease in a Child

Prescribing Immunoglobulin Replacement Therapy for Patients with Non-classical and Secondary Antibody Deficiency: an Analysis of the Practice of Clinical Immunologists in the UK and Republic of Ireland

Reversible Suppression of Lymphoproliferation and Thrombocytopenia with Rapamycin in a Patient with Common Variable Immunodeficiency

Impact of Using Different Response Criteria for Pneumococcal Polysaccharide Vaccination for Assessment of Humoral Immune Status

Correction to: Chronic Granulomatous Disease in a Brazilian Patient Mimetizing Sarcoidosis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin